Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elamin H Elbasha

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Pharmacoeconomics|June 17, 2022
Authors' Reply to Comment on "Risk-Adjusted Performance Measures"Elamin H Elbasha
Health Economics|September 24, 2004
Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approachElamin H Elbasha
Health Economics|February 4, 2003
Deadweight loss of bacterial resistance due to overtreatmentElamin H Elbasha
Bulletin of Mathematical Biology|November 14, 2007
Global stability of equilibria in a two-sex HPV vaccination modelElamin H Elbasha
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 26, 2011
Prevalence of antibodies associated with herd immunity: a commentElamin H Elbasha
Pharmacoeconomics|February 9, 2022
Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility ApproachesElamin H Elbasha
Mathematical Biosciences and Engineering : MBE|August 3, 2013
Model for hepatitis C virus transmissionsElamin H Elbasha
Pharmacoeconomics|April 9, 2015
Characterizing Heterogeneity Bias in Cohort-Based ModelsElamin H Elbasha, Jagpreet Chhatwal
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 21, 2015
Theoretical Foundations and Practical Applications of Within-Cycle Correction MethodsElamin H Elbasha, Jagpreet Chhatwal
Pharmacoeconomics|December 9, 2015
Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision MakersElamin H Elbasha, Jagpreet Chhatwal
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Pharmacoeconomics|June 17, 2022
Authors' Reply to Comment on "Risk-Adjusted Performance Measures"Elamin H Elbasha
Health Economics|September 24, 2004
Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approachElamin H Elbasha
Health Economics|February 4, 2003
Deadweight loss of bacterial resistance due to overtreatmentElamin H Elbasha
Bulletin of Mathematical Biology|November 14, 2007
Global stability of equilibria in a two-sex HPV vaccination modelElamin H Elbasha
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 26, 2011
Prevalence of antibodies associated with herd immunity: a commentElamin H Elbasha
Pharmacoeconomics|February 9, 2022
Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility ApproachesElamin H Elbasha
Mathematical Biosciences and Engineering : MBE|August 3, 2013
Model for hepatitis C virus transmissionsElamin H Elbasha
Pharmacoeconomics|April 9, 2015
Characterizing Heterogeneity Bias in Cohort-Based ModelsElamin H Elbasha, Jagpreet Chhatwal
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 21, 2015
Theoretical Foundations and Practical Applications of Within-Cycle Correction MethodsElamin H Elbasha, Jagpreet Chhatwal
Pharmacoeconomics|December 9, 2015
Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision MakersElamin H Elbasha, Jagpreet Chhatwal
Pageof 7